Takeda-led trial of COVID-19 plasma treatment delayed

The CoVIg-19 Plasma Alliance, led by Takeda Pharmaceutical Co, have completed test supplies of a hyperimmune globulin therapy derived from convalescent plasma for COVID-19, but pending regulator approval will likely prevent clinical trials from meeting a July start date.

Source:

Reuters Health